Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol by Nicolas Penel, Dominique Vaur, Juliette Thariat, Alexandre Escande, Jennifer le Guevelou, Colin Debaigt, Esma Saada-Bouzid, Julien Viotti, Nazim Khalladi, David Thibouw, Marie Pierre Sunyach, Laurence Moureau-Zabotto, Mohamed Benchalal, Ovidiu Veresezan, Anne Ducassou, Cecile le Pechoux, Maria Jolnerovski, Celine Bazille, Raphael Serre, Christine Lovera

“…In order to shift the balance towards antitumour immunity by multisite irradiation, radiation could be combined with inhibitors of the immunosuppressive pathways.Methods and analysis STEREOSARC is a prospective, multicentric, randomised phase II, designed to evaluate the efficacy of SBRT associated with immunotherapy versus SBRT only. Randomisation is performed with a 2:1 ratio within two arms. …”
Get full text

Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell car... by Wei-Xiang Qi, Shuyan Li, Shujun Zhang, Chao Li, Huan Li, Xiaomei Li, Chaofen Zhao, Gang Cai, Cheng Xu, Xuan Han, Yibin Zhang, Jiayi Chen, Shengguang Zhao

“…Sparing of LOARs using advanced radiation techniques might reduce the risk of developing lymphopenia and improve treatment response in the era of immunotherapy.…”
Get full text

Microwave Ablation Combined with Flt3L Provokes Tumor‐Specific Memory CD8+ T Cells‐Mediated Antitumor Immunity in Response to PD‐1 Blockade by Meixiang Wang, Jing Sang, Fengkuo Xu, Shulong Wang, Peng Liu, Ji Ma, Zhengtao Chen, Qi Xie, Zhigang Wei, Xin Ye

“…Finally, the combined treatment significantly enhanced the antitumor efficacy of immunotherapy based on PD‐1 blockade. The research thereby afforded a novel strategic approach to forestall tumor recurrence after MWA therapy, while also providing the foundational proof‐of‐concept for impending clinical investigations.…”
Get full text

PPARα suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release by Banglun Pan, Zhu Zhang, Dongjie Ye, Xiaoxia Zhang, Yuxin Yao, Yue Luo, Haijie Hong, Xinran Cai, Yanling Chen, Nanhong Tang

“…Conclusions: Our study not only provides insight into the relationship between lipid metabolism disorders and NETs’ tumor-promoting function, but also provides an important strategic reference for multi-target or combined immunotherapy of HCC. Impact and implications:: We have identified PPARα and its agonists as therapeutic targets for controlling the neutrophil extracellular traps associated with high lipid metabolism. …”
Get full text

Collagen turnover biomarkers to predict outcome of patients with biliary cancer by Leonard Kaps, Muhammed A. Genc, Markus Moehler, Stephan Grabbe, Jörn M. Schattenberg, Detlef Schuppan, Rasmus Sund Pedersen, Morten A. Karsdal, Philipp Mildenberger, Annett Maderer, Nicholas Willumsen

Get full text

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 express... by Fei Yang, Min Dan, Jindan Shi, Ling Fan, Haoluo Zhang, Tiantian Jian, Kelu Lei, Yue Wang, Juan Xin, Zhigang Yu, Wei Chen

“…A systematic review and Bayesian network meta-analysis were performed to assess the efficacy and safety of various immunotherapy regimens in patients with advanced ESCC. …”
Get full text

FDFT1 inhibits macrophage M1 polarization and promotes colorectal cancer progression by GAO Yuan, HUANG Yulan, ZHAO Kun

“…Conclusion‍　‍FDFT1, the metabolic enzyme in the cholesterol synthesis pathway of colorectal cancer tumor cells, is a potential target for tumor immunotherapy targeting macrophages, which promotes tumor progression by regulating macrophages. …”
Get full text

CpG-ODN Induces a Dose-Dependent Enrichment of Immunological Niches in the Spleen and Lungs of Neonatal Chicks That Correlates with the Protective Immunity against Escherichia coli by Thushari Gunawardana, Khawaja Ashfaque Ahmed, Kalhari Goonewardene, Shelly Popowich, Shanika Kurukulasuriya, Ruwani Karunarathana, Lisanework E. Ayalew, Ashish Gupta, Betty Lockerbie, Marianna Foldvari, Suresh K. Tikoo, Philip Willson, Susantha Gomis

Get full text

Adoptive cell transfer of piezo-activated macrophage rescues immunosuppressed rodents from life-threating bacterial infections by Xiaoyi Liu, Wenxiu Xu, Junkun Feng, Ying Wang, Kai Li, Yi Chen, Wenjun Wang, Weiwei Zhao, Shaohua Ge, Jianhua Li

“…Our study thus highlights the potential application of catalytic nanoparticles as a promising alternative to conventional infection treatment to effectively modulate the innate immune responses and to engineer macrophages for immunotherapy purposes.…”
Get full text

The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer by Evan D. Paul, Barbora Huraiová, Natália Valková, Natalia Matyasovska, Daniela Gábrišová, Soňa Gubová, Helena Ignačáková, Tomáš Ondris, Michal Gala, Liliane Barroso, Silvia Bendíková, Jarmila Bíla, Katarína Buranovská, Diana Drobná, Zuzana Krchňáková, Maryna Kryvokhyzha, Daniel Lovíšek, Viktoriia Mamoilyk, Veronika Mancikova, Nina Vojtaššáková, Michaela Ristová, Iñaki Comino-Méndez, Igor Andrašina, Pavel Morozov, Thomas Tuschl, Fresia Pareja, Jakob N. Kather, Pavol Čekan

“…Deploying mFISHseq as a research-use only test on 48 patients demonstrates clinical feasibility, revealing insights into the efficacy of targeted therapies, like CDK4/6 inhibitors, immunotherapies, and ADCs.…”
Get full text

Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxici... by Hazal Aslan Rejeski, Hazal Aslan Rejeski, Anne Hartz, Anne Hartz, Elias Rackl, Elias Rackl, Lin Li, Lin Li, Christoph Schwepcke, Christoph Schwepcke, Kai Rejeski, Kai Rejeski, Christoph Schmid, Christoph Schmid, Andreas Rank, Andreas Rank, Jörg Schmohl, Doris Kraemer, Peter Bojko, Helga Maria Schmetzer, Helga Maria Schmetzer

“…Overall, DCleu-based immunotherapy represents a promising treatment strategy for AML patients.…”
Get full text

Bibliometric analysis of laryngeal cancer treatment literature (2003–2023) by Yan Zhao, Jiancheng Xue

“…Notably, targeted therapy and immunotherapy are rapidly advancing fields. Conclusions: There is an urgent need to enhance global scholarly communication as the pursuit of effective laryngeal cancer treatment progresses. …”
Get full text

What Makes Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells Superior Immunomodulators When Compared to Bone Marrow Derived Mesenchymal Stromal Cells? by R. N. Bárcia, J. M. Santos, M. Filipe, M. Teixeira, J. P. Martins, J. Almeida, A. Água-Doce, S. C. P. Almeida, A. Varela, S. Pohl, K. E. J. Dittmar, S. Calado, S. I. Simões, M. M. Gaspar, M. E. M. Cruz, W. Lindenmaier, L. Graça, H. Cruz, P. E. Cruz

“…MSCs derived from the umbilical cord tissue, termed UCX, were investigated for their immunomodulatory properties and compared to bone marrow-derived MSCs (BM-MSCs), the gold-standard in immunotherapy. Immunogenicity and immunosuppression were assessed by mixed lymphocyte reactions, suppression of lymphocyte proliferation and induction of regulatory T cells. …”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

“…Further randomized controlled trials with prolonged follow-up periods are necessary to validate these results, particularly focusing on efficacy in patients with differing PD-L1 expression levels, to improve the stratified implementation of immunotherapy.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?…”
Get full text

Incidence of type 2 diabetes and metabolic syndrome by Occupation – 10-Year follow-up of the Gutenberg Health Study by Juliane Bauer, Janice Hegewald, Karin Rossnagel, Sylvia Jankowiak, Michaela Prigge, Julian Chalabi, Matthias Nübling, Alice Freiberg, Merle Riechmann-Wolf, Pavel Dietz, Philipp S. Wild, Thomas Koeck, Manfred E. Beutel, Norbert Pfeiffer, Karl J. Lackner, Thomas Münzel, Konstantin Strauch, Philipp Lurz, Oliver Tüscher, Julia Weinmann-Menke, Stavros Konstantinides, Andreas Seidler

Get full text

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III... by Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson

Get full text

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study by Chenyu Mao, Anwen Xiong, Jiong Qian, Wenxiang Wang, Ying Liu, Tao Zhang, Zhihai Wu, Haiqing Ni, Jia Lu, Sixiang Long, Li Zhao, Yuling Chen, Caicun Zhou, Nong Xu

“…Abstract Background Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunotherapy through synergistic effects. Herein, we evaluate the safety and efficacy of IBI110 (anti-LAG-3 antibody) with sintilimab (an anti-PD-1 antibody) in Chinese patients with advanced solid tumors. …”
Get full text

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy by Yishen Tian, Jingxuan Li, Na Yang, Yang Zhao, Jiancao Zuo, Hang Xiong, Yiwen Pan, Li Xiao, Min Su, Feng Han, Zhixu He, Rong Hu

“…This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.…”
Get full text

Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade glioma by Anahita Fathi Kazerooni, Adam Kraya, Komal S. Rathi, Meen Chul Kim, Arastoo Vossough, Nastaran Khalili, Ariana M. Familiar, Deep Gandhi, Neda Khalili, Varun Kesherwani, Debanjan Haldar, Hannah Anderson, Run Jin, Aria Mahtabfar, Sina Bagheri, Yiran Guo, Qi Li, Xiaoyan Huang, Yuankun Zhu, Alex Sickler, Matthew R. Lueder, Saksham Phul, Mateusz Koptyra, Phillip B. Storm, Jeffrey B. Ware, Yuanquan Song, Christos Davatzikos, Jessica B. Foster, Sabine Mueller, Michael J. Fisher, Adam C. Resnick, Ali Nabavizadeh

“…Early prediction of treatment responsiveness and suitability for immunotherapy has the potential to improve clinical management and outcomes. …”
Get full text

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer by Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia

“…Efficacy of pralsetinib was decreased in patients previously treated with PBC, immunotherapy, or MKIs.…”
Get full text